SIGA
SIGA Technologies, Inc.6.28
-0.04-0.63%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
449.72MP/E (TTM)
6.10Basic EPS (TTM)
1.03Dividend Yield
0%Recent Filings
10-Q
8-K
10-Q
Q2 FY2025 results
SIGA Technologies posted robust Q2 FY2025 results, with revenues surging 272% y/y to $81.1M, driven by $79.1M in product sales under the 19C BARDA contract, including $53.3M oral TPOXX and $25.8M IV TPOXX deliveries to the U.S. government. Gross margin held steady at 67.6% despite a $0.9M inventory write-off, while operating income leaped to $45.7M from $1.1M y/y, reflecting efficient execution on procurement milestones. Diluted EPS hit $0.49 on 71.7M shares, aligning with net income of $35.5M after a 24.9% tax provision. Cash swelled to $182.5M after $70.1M operating inflows, offset by a $43.5M special dividend; free cash flow reached $70.1M (derived). BARDA added $13.2M for pediatric TPOXX development in June 2025. Yet regulatory scrutiny from EMA's mpox trial review poses approval risks.
8-K
SIGA Q2 revenues soar to $79M
SIGA Technologies reported robust Q2 2025 results, with product sales surging to $79.1 million from $20.7 million a year ago, driven by $53 million in oral TPOXX and $26 million in IV TPOXX deliveries to the Strategic National Stockpile. Total revenues hit $81.1 million, yielding operating income of $45.7 million and net income of $35.5 million, or $0.49 per diluted share. BARDA added $27 million in development funding under the 19C contract for pediatric programs and manufacturing. Yet contract modifications pose risks to ongoing performance.
8-K
SIGA updates bylaws, elects board
SIGA Technologies amended its bylaws on June 10, 2025, designating Delaware's Court of Chancery as the exclusive forum for certain corporate claims and U.S. federal courts for Securities Act violations, aiming to streamline litigation. At the same annual meeting, shareholders elected eight directors with strong support—over 90% for most—ratified PwC as auditors, and approved an officer liability-limiting charter amendment by a wide margin. Directors stay. This bolsters governance clarity amid routine oversight.
IPO
Website
Employees
Sector
Industry
DVAX
Dynavax Technologies Corporatio
10.78-0.07
EBS
Emergent BioSolutions Inc.
12.19-0.14
HSTI
High Sierra Technologies Inc.
1.40+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NIKA
NIKA PHARMACEUTICALS INC.
0.28+0.00
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
SIGY
Sigyn Therapeutics Inc.
1.71-0.19
SNGX
Soligenix, Inc.
1.52-0.03
ZYBT
Zhengye Biotechnology Holding L
1.86-0.07